Udaya Pratap Singh

About

Udaya Pratap Singh was born in Allahabad, Uttar Pradesh, India. He received his B. Pharm. and M. Pharm. degree from Allahabad Agricultural Institute, Allahabad, India and Dibrugarh University, India. He was awarded with a scholarship from the Government of Uttar Pradesh and from the Ministry of Human Resource and ­Development, Government of India. Presently, he is working as an Assistant Professor in Pharmaceutical Chemistry at the Sam ­Higginbottom Institute of Agriculture, Technology & Sciences (SHIATS) and had completed doctoral studies under the supervision of Dr. Ramendra K. Singh, Nucleic Acids Research Laboratory, University of Allahabad. His research interest is focused on the development of novel heterocyclic scaffolds and their medicinal importance through facile synthetic routes. Recently, he had been awarded with Archimedes Foundation, DoRa5 Scholarship to carry out part of his PhD work under the supervision of Prof. Asko Uri, Institute of Chemistry, University of Tartu. Apart from it, Dr. Singh have authored to more than thirty-five international research articles, won many prestigious travel grant/awards/bursary, and acting as reviewer to many highly reputed journals. He has widely travel across the globe for presenting his research papers.

Employment

• Sam Higginbottom University of Agriculture Technology and Sciences Assistant Profesor
  2008 - Present

Education

• Sam Higginbottom Institute of Agriculture, Technology & Sciences, Faculty of Health Sciences PhD in Pharmaceutical Sciences
  2010 - 2014
• Dibrugarh University M. Pharm
  2006 - 2008
• Allahabad Agricultural Institute-Deemed University B. Pharm
  2002 - 2006

Projects & Funding

Projects & funding information is unavailable.

Publications (65)

• Design and development of novel N-(4-aminobenzoyl)- l-glutamic acid conjugated 1,3,5-triazine derivatives as Pf-DHFR inhibitor: An in-silico and in-vitro study
  Journal of Biochemical and Molecular Toxicology 2023 DOI: 10.1002/jbt.23290
  +Save
• In silico screening, synthesis, and antimalarial evaluation of PABA substituted 1,3,5-triazine derivatives as Pf-DHFR inhibitors
  Experimental Parasitology 2023 DOI: 10.1016/j.exppara.2023.108546
  +Save
• Therapeutic potential of Reserpine in metabolic syndrome
  Pharmacological Research 2023 DOI: 10.1016/j.phrs.2023.106719
  +Save
• Aminoquinoline-triazine Conjugates: Design, Synthesis, Antibacterial Activity, and SAR Analysis
  Letters in Drug Design and Discovery 2023 DOI: 10.2174/1570180819666220420084401
  +Save
• Implication of in silico studies in the search for novel inhibitors against SARS-CoV-2
  Archiv der Pharmazie 2022 DOI: 10.1002/ardp.202100360
  +Save
• Implicit, Intrinsic, Extrinsic, and Host Factors Attributing the COVID-19 Pandemic. Part 3- Host Factor GDP: A Systematic Analysis
  ResearchSquare 2022 DOI: 10.21203/rs.3.rs-1498170
  +Save
• Molecular docking and antimalarial evaluation of novel N-(4-aminobenzoyl)-l-glutamic acid conjugated 1,3,5-triazine derivatives as Pf-DHFR inhibitors
  3 Biotech 2022 DOI: 10.1007/s13205-022-03400-2
  +Save
• 1,3,5-Triazine: A versatile pharmacophore with diverse biological activities
  Archiv der Pharmazie 2021 DOI: 10.1002/ardp.202000363
  +Save
• Discovery of novel 1,3,5-triazine as adenosine A2A receptor antagonist for benefit in Parkinson's disease
  Journal of Biochemical and Molecular Toxicology 2021 DOI: 10.1002/jbt.22659
  +Save
• Discovery of novel pyrazole derivatives as a potent anti-inflammatory agent in RAW264.7 cells via inhibition of NF-ĸB for possible benefit against SARS-CoV-2
  Journal of Biochemical and Molecular Toxicology 2021 DOI: 10.1002/jbt.22656
  +Save